Recursion Pharmaceuticals, Inc., a prominent player in the health care sector, has been making significant strides in the biotechnology industry through its innovative use of artificial intelligence (AI) and automation. The company specializes in conducting experimental biology on parallel testing compounds for cellular disease models, positioning itself at the forefront of cutting-edge research and development.
As of March 12, 2026, Recursion Pharmaceuticals’ stock was trading at a close price of $3.42 on the Nasdaq exchange. This figure represents a notable fluctuation within the year, as the company’s stock reached a 52-week high of $7.18 on October 19, 2025, and a 52-week low of $2.98 on February 17, 2026. These fluctuations reflect the dynamic nature of the biotechnology sector and the market’s response to the company’s ongoing developments and strategic initiatives.
With a market capitalization of approximately $1.81 billion, Recursion Pharmaceuticals continues to attract attention from investors and stakeholders. Despite a negative price-to-earnings ratio of -2.3, indicative of the company’s current financial performance challenges, the firm remains committed to its long-term vision of revolutionizing drug discovery and development.
Recursion Pharmaceuticals operates globally, serving customers through its online platform at www.recursionpharma.com . The company’s approach leverages AI and automation to enhance the efficiency and accuracy of its experimental processes, aiming to accelerate the identification of potential therapeutic compounds.
The company’s innovative methodologies are designed to address complex cellular disease models, offering a promising avenue for the development of novel treatments. By integrating advanced technologies into its research framework, Recursion Pharmaceuticals seeks to streamline the drug discovery pipeline, ultimately contributing to improved patient outcomes and advancing the field of biotechnology.
As Recursion Pharmaceuticals continues to navigate the challenges and opportunities within the health care sector, its commitment to leveraging AI and automation remains a cornerstone of its strategy. The company’s efforts to harness these technologies underscore its dedication to pioneering new solutions in the realm of experimental biology and cellular disease research.
